scholarly journals Evaluation of the 8th edition of the American joint committee on cancer’s pathological staging system in prognosis assessment and treatment decision making for stage T1-2N1 breast cancer after mastectomy

The Breast ◽  
2020 ◽  
Vol 51 ◽  
pp. 2-10
Author(s):  
San-Gang Wu ◽  
Jun Wang ◽  
Chen-Lu Lian ◽  
Jian Lei ◽  
Li Hua ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Decision Making ◽  
Treatment Decision ◽  
Staging System ◽  
Treatment Decision Making ◽  
Pathological Staging ◽  
American Joint Committee ◽  
Assessment And Treatment ◽  
8Th Edition ◽  
Stage T1

Clinical Application of the 70-Gene Profile: The MINDACT Trial

2008 ◽  
Vol 26 (5) ◽  
pp. 729-735 ◽  
Author(s):  
Fatima Cardoso ◽  
Laura Van't Veer ◽  
Emiel Rutgers ◽  
Sherene Loi ◽  
Stella Mook ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Assessment ◽  
Decision Making ◽  
Early Breast Cancer ◽  
Treatment Decision ◽  
Clinical Validation ◽  
Gene Profile ◽  
Node Negative ◽  
Treatment Decision Making ◽  
Assessment And Treatment

The 70-gene profile is a new prognostic tool that has the potential to greatly improve risk assessment and treatment decision making for early breast cancer. Its prospective validation is currently ongoing through the MINDACT (Microarray in Node-Negative Disease May Avoid Chemotherapy) trial, a 6,000-patient randomized, multicentric trial. This article reviews the several steps in the development of the profile from its discovery to its clinical validation.

Enhancing Involvement in Treatment Decision Making by Women with Breast Cancer

2007 ◽  
Author(s):  
Mary A. O'Brien ◽  
Timothy Whelan ◽  
Amiram Gafni ◽  
Cathy Charles ◽  
Peter Ellis
Keyword(s):  
Breast Cancer ◽  
Decision Making ◽  
Treatment Decision ◽  
Treatment Decision Making

Gene Expression Assay in the Management of Early Breast Cancer

2020 ◽  
Vol 27 (17) ◽  
pp. 2826-2839 ◽  
Author(s):  
Roberta Caputo ◽  
Daniela Cianniello ◽  
Antonio Giordano ◽  
Michela Piezzo ◽  
Maria Riemma ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Decision Making ◽  
Adjuvant Chemotherapy ◽  
Early Breast Cancer ◽  
Treatment Decision ◽  
Endocrine Treatment ◽  
Expression Ratio ◽  
Treatment Decision Making ◽  
Low Sensitivity

The addition of adjuvant chemotherapy to hormonal therapy is often considered questionable in patients with estrogen receptor-positive early breast cancer. Low risk of disease relapse after endocrine treatment alone and/or a low sensitivity to chemotherapy are reasons behind not all patients benefit from chemotherapy. Most of the patients could be exposed to unnecessary treatment- related adverse events and health care costs when treatment decision-making is based only on classical clinical histological features. Gene expression profile has been developed to refine physician’s decision-making process and to tailor personalized treatment to patients. In particular, these tests are designed to spare patients the side effects of unnecessary treatment, and ensure that adjuvant chemotherapy is correctly recommended to patients with early breast cancer. In this review, we will discuss the main diagnostic tests and their potential clinical applications (Oncotype DX, MammaPrint, PAM50/Prosigna, EndoPredict, MapQuant Dx, IHC4, and Theros-Breast Cancer Gene Expression Ratio Assay).

Breast cancer patients' personality style, age, and treatment decision making

1996 ◽  
Vol 63 (3) ◽  
pp. 183-186 ◽  
Author(s):  
Julie D. Johnson ◽  
Cleora S. Roberts ◽  
Charles E. Cox ◽  
Douglas S. Reintgen ◽  
Judi S. Levine ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Decision Making ◽  
Cancer Patients ◽  
Treatment Decision ◽  
Breast Cancer Patients ◽  
Personality Style ◽  
Treatment Decision Making
Sign in / Sign up

Export Citation Format

Share Document